Pharmacokinetics of Ibuprofen in Children with Cystic Fibrosis

Clinical Pharmacokinetics

Volumn 43, Issue 3, 2004, Pages 145-156

  Han, Emily E ^a   Beringer, Paul M ^a,b,c   Louie, Stan G ^a,b   Gill, Mark A ^a   Shapiro, Bertrand J ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; ANTIINFLAMMATORY AGENT; CIMETIDINE; CORTICOSTEROID; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; KETOCONAZOLE; NIZATIDINE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; PROTON PUMP INHIBITOR; RANITIDINE;

ABDOMINAL PAIN; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; BAYES THEOREM; CATARACT; CLINICAL TRIAL; CONJUNCTIVITIS; CYSTIC FIBROSIS; DIGESTIVE SYSTEM ULCER; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG FORMULATION; DRUG MONITORING; DRUG PROTEIN BINDING; DRUG SAFETY; EPISTAXIS; FOOD DRUG INTERACTION; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL HEMORRHAGE; GROWTH RETARDATION; HUMAN; KIDNEY FAILURE; LONG TERM CARE; LUNG DISEASE; MENTAL INSTABILITY; NEUTROPENIA; NONHUMAN; NUTRITIONAL STATUS; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; REVIEW; SAMPLING; SIDE EFFECT; VESTIBULAR DISORDER;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHILD; CYSTIC FIBROSIS; DRUG INTERACTIONS; DRUG MONITORING; HUMANS; IBUPROFEN;

EID: 1442310993     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200443030-00001     Document Type: Review

References (39)

1. Cystic Fibrosis Foundation. Cystic fibrosis foundation patient registry annual data report 1998. Bethesda (MD): Cystic Fibrosis Foundation, 1998 Sep
2. Iannuzzi M, Dean M, Drumm M, et al. Isolation of additional polymorphic clones from the cystic fibrosis region, using chromosome jumping from D7S8. Am J Hum Genet 1989; 44 (5): 695-703
3. Kerem B, Rommens J, Buchanan J, et al. Identification of the cystic fibrosis gene: genetic analysis. Science 1989; 245 (4922): 1073-89
4. Davis PB, Drumm M, Konstan MW. Cystic fibrosis. Am J Respir Crit Care Med 1996; 154: 1129-256
5. Lyczak JB, Cannon CL, Pier GB. Lung infections associated with cystic fibrosis. Clin Microbiol Rev 2002; 15 (2): 194-222
6. Bonfield TL, Panuska JR, Konstan MW, et al. Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med 1995; 152: 2111-8
7. Bonfield TL, Konstan MW, Berger M. Altered respiratory epithelial cell cytokine production in cystic fibrosis. J Allergy Clin Immunol 1999; 104 (1): 72-8
8. Konstan MW, Berger M. Current understanding of the inflammatory process in cystic fibrosis: onset and etiology. Pediatr Pulmonol 1997; 24: 137-42
9. Rosenstein BJ, Eigen H. Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics 1991; 87 (2): 245-6
10. Insel P. Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment of gout. In: Hardman J, Limbird L, Molinoff P, et al., editors. The pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996: 617-57
11. Davies NM. Clinical pharmacokinetics of ibuprofen: the first 30 years. Clin Pharmacokinet 1998; 34 (2): 101-54
12. Kirchheiner J, Meineke I, Freytag G, et al. Enantiospecific effects of cytochrome p450 2c9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2. Clin Pharmacol Ther 2002; 72 (1): 62-75
13. Konstan MW, Vargo KM, Davis PB. Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginosa in a rat model of chronic pulmonary infection. Am Rev Respir Dis 1990; 141: 186-92
14. Konstan MW, Byard PJ, Hoppel CL, et al. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995; 332 (13): 848-54
15. Konstan MW, Krenicky JE, Finney MR, et al. Effect of ibuprofen on neutrophil migration in vivo in cystic fibrosis and healthy subjects. J Pharmacol Exp Ther 2003; 306: 1086-91
16. Lockwood GF, Albert KS, Szpunar GJ, et al. Pharmacokinetics of ibuprofen in man. III: plasma protein binding. J Pharmacokinet Biopharm 1983; 11 (5): 469-82
17. Lockwood GF, Albert KS, Gillespie WR, et al. Pharmacokinetics of ibuprofen in man. I: free and total area/dose relationships. Clin Pharmacol Ther 1983; 34 (1): 97-103
18. Lee EJ, Willliams K, Day R, et al. Stereoselective disposition of ibuprofen enantiomers in man. Br J Clin Pharmacol 1985; 19: 669-74
19. Tan SC, Patel BK, Jackson SHD, et al. Stereoselectivity of ibuprofen metabolism and pharmacokinetics following the administration of the racemate to healthy volunteers. Xenobiotica 2002; 32 (8): 683-97
20. Spino M. Pharmacokinetics of drugs in cystic fibrosis. Clin Rev Allergy 1991; 9 (1-2): 169-210
21. Touw DJ, Vinks AA, Mouton JW, et al. Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis: current practice and suggestions for future directions. Clin Pharmacokinet 1998; 35 (6): 437-59
22. Rey E, Treluyer J, Pons G. Drug disposition in cystic fibrosis. Clin Pharmacokinet 1998; 35 (4): 313-29
23. Konstan MW, Hoppel CL, Chai B, et al. Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. J Pediatr 1991; 118: 956-64
24. Murry DJ, Oermann CM, Ou C, et al. Pharmacokinetics of ibuprofen in patients with cystic fibrosis. Pharmacotherapy 1999; 19 (3): 340-5
25. Rifai N, Sakamoto M, Law T, et al. Use of a rapid hplc assay for determination of pharmacokinetic parameters of ibuprofen in patients with cystic fibrosis. Clin Chem 1996; 42 (11): 1812-6
26. Scott CS, Retsch-Bogart GZ, Kustra RP, et al. The pharmacokinetics of ibuprofen suspension, chewable tablets, and tablets in children with cystic fibrosis. J Pediatr 1999; 134 (1): 58-63
27. Williams R, Chen M, Hauck W. Equivalence approaches. Clin Pharmacol Ther 2002; 72 (3): 229-37
28. Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 2002; 71 (3); 115-21
29. Kearns GLP, Crom WRP, Karlson Jr KH, et al. Hepatic drug clearance in patients with mild cystic fibrosis. Clin Pharmacol Ther May 1996; 59 (5): 529-40
30. Dong JQ, Ni L, Scott CS, et al. Pharmacokinetics of ibuprofen enantiomers in children with cystic fibrosis. J Clin Pharmacol 2000; 40 (8): 861-8
31. CF Ibuprofen Laboratory. Questions and answers ibuprofen: information for cystic fibrosis physicians 1995 [online]. Available from URL: http://www.cwru.edu/affil/CFIBUPLAB/physgen.htm [Accessed 2002 Sep 17]
32. Beringer P, Aminimanizani A, Synold T, et al. Development of population pharmacokinetic models and optimal sampling times for ibuprofen tablet and suspension formulations in children with cystic fibrosis. Ther Drug Monit 2002; 24: 315-21
33. Bell EA, Grothe R, Zivkovich V, et al. Pyloric channel stricture secondary to high-dose ibuprofen therapy in a patient with cystic fibrosis. Ann Pharmacother 1999; 33: 693-6
34. Scott CS, Retsch-Bogart GZ, Henry MM. Renal failure and vestibular toxicity in an adolescent with cystic fibrosis receiving gentamicin and standard-dose ibuprofen. Pediatr Pulmonol 2001; 31 (4): 314-6
35. Kimura RE, Dy SA, Uhing MR, et al. The effects of high-dose ibuprofen and pancreatic enzymes on the intestine of the rat. J Pediatr Gastroenterol Nutr 1999; 29 (2): 178-83
36. Feigelson J, Girault F, Pecau Y. Gastro-esophageal reflux and esophagitis in cystic fibrosis. Acta Paediatr Scand 1987; 76 (6): 989-90
37. Forsyth DR, Jayasinghe KSA, Roberts CJC. Do nizatidine and cimetidine interact with ibuprofen? Eur J Clin Pharmacol 1988; 35 (1): 85-8
38. Ochs HR, Greenblatt DJ, Matlis R, et al. Interaction of ibuprofen with the H2 receptor antagonists ranitidine and cimetidine. Clin Pharmacol Ther 1985; 38 (6): 648-51
39. Conrad KA, Mayersohn M, Bliss M. Cimetidine does not alter ibuprofen kinetics after a single dose. Br J Clin Pharmacol 1984; 18(4): 624-6